"10.1371_journal.pone.0035351","plos one","2012-04-24T00:00:00Z","Glen A Coburn; Danielle N Fisch; Sameer M Moorji; Jean-Marc de Muys; Jose D Murga; Dorothy Paul; Kathleen P Provoncha; Yakov Rotshteyn; Amy Q Han; Dapeng Qian; Paul J Maddon; William C Olson","Research and Development, Progenics Pharmaceuticals, Inc., Tarrytown, New York, United States of America","Conceived and designed the experiments: GAC JMDM AQH PJM WCO. Performed the experiments: DNF SMM JMDM JDM DP KPP. Analyzed the data: GAC DNF SMM JMDM JDM DP KPP YR AQH DQ PJM WCO. Contributed reagents/materials/analysis tools: DNF SMM JMDM JDM DP KPP. Wrote the paper: GAC WCO. Designed all small-molecule compounds used in these studies: AQH. Conducted all DMPK studies: YR.","All authors were employees of Progenics Pharmaceuticals, Inc. during these studies. This manuscript describes the independent discovery of a series of triazine compounds that were first reported by the group in a published WIPO patent application on July 23, 2009 (Publication No: WO2009/091388; International Patent Application Number: PCT/US2008/013964) and later by a group at Bristol-Myers Squibb [Baldick et al. (2010) PLoS Pathogens 6, e1001086]. There are no further products in development or marketed products to declare. This does not alter the authors adherence to all the PLoS ONE policies on sharing data and material.","2012","04","Glen A Coburn","GAC",12,TRUE,5,6,12,2,TRUE,TRUE,FALSE,0,NA,FALSE
